Canagliflozin bei diabetischer Nierenerkrankung
Crossref DOI link: https://doi.org/10.1007/s11428-023-01110-8
Published Online: 2023-10-24
Published Print: 2023-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Pavlicek, Vojtech
Text and Data Mining valid from 2023-10-24
Version of Record valid from 2023-10-24
Article History
Accepted: 28 September 2023
First Online: 24 October 2023
Interessenkonflikt
: V. Pavlicek: Teilnahme an „advisory boards“ für MSD, Sanofi Aventis, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Eli-Lilly, Bayer.